Jazz Pharm., Inc. v. Synchrony Grp., LLC

343 F. Supp. 3d 434
CourtDistrict Court, E.D. Pennsylvania
DecidedDecember 3, 2018
DocketCIVIL ACTION NO. 18-602
StatusPublished
Cited by19 cases

This text of 343 F. Supp. 3d 434 (Jazz Pharm., Inc. v. Synchrony Grp., LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jazz Pharm., Inc. v. Synchrony Grp., LLC, 343 F. Supp. 3d 434 (E.D. Pa. 2018).

Opinion

Rufe, J.

Plaintiff Jazz Pharmaceuticals, Inc. filed suit against Defendants Synchrony Group, LLC and its related entities (collectively, "Synchrony") for violations of the federal Defend Trade Secrets Act ("DTSA"),1 the Pennsylvania Uniform Trade Secrets Act ("PUTSA"),2 breach of contract, breach of duty of loyalty, and breach of fiduciary duty. Synchrony now moves to dismiss the Complaint for lack of subject matter jurisdiction and for failure to state a claim upon which relief can be granted. For the following reasons, the motion will be granted in part and denied in part.

I. BACKGROUND3

Jazz is a California-based pharmaceutical company which manufactures various sleep medications, including Xyrem-an FDA-approved prescription drug used to treat narcolepsy. As part of efforts to expand the number of patients benefitting from Xyrem and its other sleep-related drugs, Jazz engaged in business discussions with Synchrony, a Pennsylvania-based pharmaceutical marketing firm, to develop and execute marketing support and evaluation services.

On March 1, 2012, Jazz and Synchrony entered into a Master Services Agreement *439("MSA"), which was later amended to extend its term to March 1, 2018. The MSA, as amended, detailed the scope of the parties' relationship and included provisions to protect Jazz's confidential information. The protected information included various forms of data and technology, as well as business, financial, marketing, and manufacturing processes related to Jazz's products. The MSA also required Synchrony to refrain from using or disclosing Jazz's outlined confidential information at any time or for any purpose either during, or after, the term of the MSA, without Jazz's prior written consent. If a party prematurely terminated the MSA or if Jazz requested, Synchrony had to return or destroy all confidential information.

Over the course of the next several years, Synchrony accessed valuable information concerning all aspects of Jazz's medical marketing and development plans for Xyrem and other sleep-related drugs. Jazz provided Synchrony with marketing strategies and tactics for promoting its products, non-public drug sales data and data regarding physician-prescribing habits, market research commissioned by Jazz surveying patients' and doctors' habits and preferences, Jazz's analyses of its own products compared to other narcolepsy products, and risk evaluation and mitigation strategy research and information. To restrict the accessibility of such information, Jazz imposed strict limitations on its dissemination through employee confidentiality agreements, non-disclosure agreements with third parties, employee handbook policies, and coded access cards to lock and monitor Jazz's physical facilities.

By November 21, 2017, approximately three months prior to the end of the MSA term, Synchrony's CEO informed Jazz of its potential interest in working with Harmony, a newly formed pharmaceutical company which had recently acquired a narcolepsy drug, pitolisant, not yet approved in the United States. Synchrony planned to move "the best of its personnel" to a different division to focus on other clients, such as Harmony. Approximately one week later, Synchrony notified Jazz that it had signed a services agreement to act as the agency of record for Harmony. The next day, Synchrony sent a letter to Jazz, declaring its desire to terminate all sleep-related projects with Jazz, despite the existence of twenty open projects relating to Xyrem and other sleep-related drugs.

Even though Jazz attempted throughout December of 2017 and January of 2018 to negotiate a business solution to continue its collaboration with Synchrony, Synchrony failed to respond to such requests. The CEO of Synchrony did, however, admit that he had given Harmony the names of several Jazz employees in commercial, medical affairs, and regulatory roles that Harmony should consider trying to hire to build its narcolepsy treatment business. Synchrony then returned some, but not all, of Jazz's confidential information.

Jazz filed suit, asserting claims against Synchrony for violations of the DTSA (Count I), PUTSA (Count II), breach of contract (Count III), breach of duty of loyalty (Count IV), and breach of fiduciary duty (Count V). Jazz also filed a motion for a temporary restraining order and preliminary injunction, demanding that Synchrony immediately return all information relating to its work for Jazz, refrain from using or disclosing Jazz's confidential information and trade secrets, and desist from providing services to Harmony.

Synchrony agreed to comply with a voluntary stipulated preliminary injunction, which the Court approved. Under the injunction, Synchrony agreed to return all listed confidential information to Jazz, refrain from using or disclosing Jazz's confidential *440information and trade secrets, and produce Synchrony's CEO for deposition concerning Synchrony's use of Jazz's confidential information.

II. LEGAL STANDARDS

A. Federal Rule of Civil Procedure 12(b)(1)

Federal Rule of Civil Procedure 12(b)(1) permits a party to move for dismissal of any claim over which the district court lacks subject matter jurisdiction.4 A motion to dismiss under Rule 12(b)(1) therefore challenges the power of a federal court to hear a claim or case.5 When faced with a 12(b)(1) motion, the plaintiff must bear the burden of persuasion to convince the court that it has jurisdiction.6

Proper grounds for a Rule 12(b)(1) motion to dismiss includes the issue of mootness, since the mootness doctrine implicates jurisdictional matters.7 A plaintiff's claim is rendered moot "when 'the issues presented are no longer live or the parties lack a legally cognizable interest in the outcome.' "8 The central question of all mootness issues, then, "is whether changes in circumstances that prevailed at the beginning of the litigation have forestalled any occasion for meaningful relief."9

B. Federal Rule of Civil Procedure 12(b)(6)

Pursuant to Federal Rule of Civil Procedure 12(b)(6), dismissal of a complaint for failure to state a claim upon which relief can be granted is appropriate where a plaintiff's "plain statement" lacks enough substance to demonstrate that he is entitled to relief.10 In determining whether a motion to dismiss should be granted, the court must consider only those facts alleged in the complaint, accepting the allegations as true and drawing all logical inferences in favor of the non-moving party.11 Courts are not, however, bound to accept as true legal conclusions framed as factual allegations.12 Something more than a mere possibility

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
343 F. Supp. 3d 434, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jazz-pharm-inc-v-synchrony-grp-llc-paed-2018.